Meet the Pentara Team at Booth #3711
Come to chat with us to see how we’re optimizing clinical trial designs and making complex clinical data easier to understand!
Suzanne Hendrix, Ph.D.
Estimating The 10-Year Time-Savings Benefits of Lecanemab Treatment
Date: 2026-04-19
Time: 2:00 PM
Location: S1: New Perspectives on Alzheimer's Therapeutics
Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance - Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials
Date: 2026-04-19
Time: 8:00 AM
Location: P1 #015 in Neighborhood 12
Samuel Dickson, Ph.D.
Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved
Date: 2026-04-19
Time: 11:45 AM
Location: P2 #003 in Neighborhood 12
Patrick O'Keefe, Ph.D.
Evaluating the potential of basket trial design in neurodegenerative diseases
Mitchell Wassom, M.S.
Practice Effects: How an Assessment’s Liability can be Turned Into an Asset in Randomized Control Trials for Early Alzheimer’s Disease
Prince Agyapong, M.S.
The Gray Zone Loophole: How Excluding Borderline Results Creates Misleading Diagnostic Performance Claims in Alzheimer’s Disease Studies
Meet the Pentara Team at Booth #100
Come to chat with us to see how we’re optimizing clinical trial designs and making complex clinical data easier to understand!
Suzanne Hendrix, Ph.D.
Continued Or Time-limited Treatment Benefits Of Anti-amyloid Monoclonal Antibodies In Early Alzheimer’s Disease
Quantifying The Improved Treatment Effect Of Lecanemab And Donanemab In Minority Populations With Comorbidities
Samuel Dickson, Ph.D.
Racial-specific biomarker cutoff is needed to increase inclusion in Alzheimer’s clinical trials
Garrett Duncan, M.S.
Quantifying The Synergistic Treatment Effect Of Lecanemab And Donanemab In Comorbid Populations
Caleb Dayley, M.S.
Optimizing Pre-Symptomatic Alzheimer’s Trials: A Power Comparison of Continuous Endpoints vs. Time-to-Event Analysis
Patrick O'Keefe, Ph.D.
GSTs in the Framework of Structural Equation Models: Type I error and power
Caleb Dayley, M.S.
Why Placebo Progression Should Be the Gold Standard for Endpoint Validation in Clinical Trials for Progressive Diseases
John Whetten, M.S.
Estimating Time Savings for Individual Participants in Clinical Trials for Progressive Diseases
Daniel Smith, M.S.
Comparing Parametric and Non-Parametric Time Saving Estimates in Clinical Trials